Clinical Trials in Baltimore

Showing 1301-1320 of 11,213 trials

Gracie Diet for Gastroesophageal Reflux Disease

NCT04360252

The goal of this clinical trial is to learn if dietary changes can help improve gastroesophageal reflux disease (GERD) symptoms. The main question\[s\] it aims to answer whether the Gracie Diet is an option to treat GERD symptoms in individuals wish to discontinue standard doses of PPI and / or H2 receptor antagonists. Participants will be taken off PPI and be placed on the Gracie Diet for 8 weeks. Information about the participants reflux symptoms and GERD health related quality of life will be collected to assess the effect of the diet.

Gastroesophageal RefluxGERD

Johns Hopkins University30 participantsStarted Nov 2020

Baltimore, Maryland, United States

Active Not RecruitingPhase 3< 1 mile

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

ER-Positive HER2-Negative Breast Cancer

AstraZeneca315 participantsStarted Jun 2021

Phoenix, Arizona, United States • Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States +262 more locations

Gracie Diet for Gastroesophageal Reflux Disease

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Find Trials by Condition in Baltimore

CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

855303-RNA Biomarker Validation

Perf-Fix Study for Chronic Tympanic Membrane Repair

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

Prostate Active Surveillance Study

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Prevention of Injury in Skilled Nursing Facilities Through Optimizing Medications

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)